In plain language
Ipamorelin is a synthetic peptide that mimics ghrelin to stimulate the pituitary to release growth hormone. It is described as more selective than older secretagogues, with less effect on other hormones in animal studies. Human evidence remains limited, so its long-term effects are not established.
What it is explored for
Ipamorelin is appealing for its selectivity: it is described as prompting a clean, focused release of the body's own growth hormone with little effect on other hormones like cortisol or prolactin. That tidy, selective profile is why it is a favorite partner in growth-hormone-axis protocols. Here is where interest and reported use are highest.
- Supporting the body's own growth-hormone release
- A selective profile with minimal effect on other hormones
- Recovery from exercise and physical stress
- Lean muscle and body composition
- Fat metabolism support
- Better sleep quality
- Healthy aging and vitality
These are areas of active interest and reported use, not proven outcomes. This peptide carries a limited evidence rating, see the evidence summary below for how strong the science actually is.
How it works
Ipamorelin acts on the growth hormone secretagogue receptor (the ghrelin receptor) in the pituitary and hypothalamus, prompting a pulse of growth hormone release.
- Ghrelin receptor agonism. Selectively activates the GHS receptor to trigger growth hormone release.
- Reported selectivity. In animal studies it raised GH with little effect on cortisol or prolactin, unlike some older secretagogues.
- Downstream IGF-1. The released growth hormone in turn can raise circulating IGF-1.
Selectivity claims come largely from animal studies. Well-controlled human outcome trials have not been published.
Evidence summary
Evidence for ipamorelin is limited. Preclinical work and early pharmacology suggest it raises growth hormone with a relatively clean hormonal profile, but there are no published, well-controlled human trials demonstrating benefits for body composition, recovery, or other outcomes. Most marketed claims outpace the published data.
Reported safety & side effects
Ipamorelin is often described as well-tolerated in short-term and animal studies, but human safety data is sparse. Long-term effects, interactions, and risks in people are unknown.
Stacking notes
Full stacking guideA GHRH analog paired with a selective ghrelin-receptor peptide. They raise growth hormone through two different pathways, and ipamorelin is selective enough to avoid the large cortisol and prolactin spikes seen with older GHRPs.
CJC-1295MK-677 already raises growth hormone and IGF-1 strongly on its own. Adding another secretagogue compounds water retention, appetite, and insulin-resistance effects for little clear added benefit.
MK-677Stacking two peptides that hit the same ghrelin receptor (for example ipamorelin with GHRP-6 or hexarelin) is largely redundant and increases hunger, cortisol, and prolactin without a clear reason.
GHRP-6General educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.
Frequently asked
Is ipamorelin FDA-approved?
No. Ipamorelin is not approved by the FDA for any use. It is sold as a research chemical and is not an approved medicine.
How is ipamorelin different from GHRP-6?
Both stimulate the ghrelin receptor, but ipamorelin is reported in animal studies to be more selective, raising growth hormone with less effect on cortisol, prolactin, and appetite than GHRP-6.
Is there strong human evidence?
No. Most data is preclinical or early pharmacology. There are no published, well-controlled human trials showing meaningful clinical outcomes.